Home › Stories › Stocks
🟡 Watch

Merck shares the cancer vaccine news, with no price read

Merck co-owns the melanoma vaccine results with Moderna, but no Merck price was captured, so its market reaction cannot be read.

Buzz velocity5.0×

What's happening

Ars Technica reported that Merck and Moderna's mRNA cancer vaccine cut death and recurrence by 42%. A Hacker News post said the trial met its key endpoints in melanoma. A Mastodon post said both companies are already engaging with regulatory authorities to get the vaccine approved.

The numbers

No Merck price was captured, so the share reaction cannot be measured. Chatter ran at velocity 5.0 across 3 sources, with 5 recent mentions.

Our read

The attention is real and mostly attached to the Moderna name. Without a Merck price we can't say whether money is backing it. Watch for a price read and for any regulatory timeline from the two companies.

Context

No price history was captured for Merck, so this story cannot be placed against a price range or a later price move. Sort Brick's earlier Merck-Moderna story, dated 2026-08-20, covered heavy chatter around the melanoma vaccine data and was given the Watch verdict. A second earlier story, dated 2026-10-23, reported the same 42% cut in death and recurrence and was also given the Watch verdict. There are no later Sort Brick stories on Merck in the record. The chatter figures for this story were velocity 5.0 across 3 sources and 5 recent mentions.

Sources we checked

See today's live board

This story is frozen as published on October 24, 2026. The live board shows what is moving right now, scored against real money.

Open this story live → See today's live board

Earlier on Merck

More Stocks stories

Research, not financial advice. Sort Brick reports what its data showed at the time of publication. It is not a recommendation to buy or sell anything — you decide.

Get Sort Brick Daily - free, every evening

One short email every evening: what really moved, what was only noise, and what we logged first, with the times. Free. Information, not investment advice.

No spam. One click to unsubscribe. Sent by Sort Brick.